Evidence map›Paper›PMID 27596150›Full record

ArticleEBioMedicine2016

The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC).

Naveed Z Janjua, Margot Kuo, Amanda Yu, Maria Alvarez, Stanley Wong, Darrel Cook, Jason Wong, Jason Grebely, Zahid A Butt, Hasina Samji and 3 more

Open access · goldAbstract read
In one paragraph

Article in EBioMedicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 106 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Characterizing the cascade of care for hepatitis C virus infection among Status First Nations peoples in Ontario: a retrospective cohort study.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2023
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Naveed Z JanjuaBritish Columbia Centre for Disease Control (BCCDC), 655 West 12th Avenue, Vancouver, BC V5Z 4R4, Canada; School of Population and Public Health, University of British Columbia, 2206 East Mall, Vancouver, BC V6T 1Z3, Canada. Electronic address: naveed.janjua@bccdc.ca.
Margot KuoBritish Columbia Centre for Disease Control (BCCDC), 655 West 12th Avenue, Vancouver, BC V5Z 4R4, Canada.
Amanda YuBritish Columbia Centre for Disease Control (BCCDC), 655 West 12th Avenue, Vancouver, BC V5Z 4R4, Canada.
Maria AlvarezBritish Columbia Centre for Disease Control (BCCDC), 655 West 12th Avenue, Vancouver, BC V5Z 4R4, Canada.
Stanley WongBritish Columbia Centre for Disease Control (BCCDC), 655 West 12th Avenue, Vancouver, BC V5Z 4R4, Canada.
Darrel CookBritish Columbia Centre for Disease Control (BCCDC), 655 West 12th Avenue, Vancouver, BC V5Z 4R4, Canada.
Jason WongBritish Columbia Centre for Disease Control (BCCDC), 655 West 12th Avenue, Vancouver, BC V5Z 4R4, Canada; School of Population and Public Health, University of British Columbia, 2206 East Mall, Vancouver, BC V6T 1Z3, Canada.
Jason GrebelyKirby Institute, University of New South Wales Australia, Sydney, NSW 2052, Australia.
Zahid A ButtBritish Columbia Centre for Disease Control (BCCDC), 655 West 12th Avenue, Vancouver, BC V5Z 4R4, Canada; School of Population and Public Health, University of British Columbia, 2206 East Mall, Vancouver, BC V6T 1Z3, Canada.
Hasina SamjiBritish Columbia Centre for Disease Control (BCCDC), 655 West 12th Avenue, Vancouver, BC V5Z 4R4, Canada; School of Population and Public Health, University of British Columbia, 2206 East Mall, Vancouver, BC V6T 1Z3, Canada.
Alnoor RamjiDivision of Gastroenterology, Department of Medicine, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
Mark TyndallBritish Columbia Centre for Disease Control (BCCDC), 655 West 12th Avenue, Vancouver, BC V5Z 4R4, Canada; School of Population and Public Health, University of British Columbia, 2206 East Mall, Vancouver, BC V6T 1Z3, Canada.
Mel KrajdenBritish Columbia Centre for Disease Control (BCCDC), 655 West 12th Avenue, Vancouver, BC V5Z 4R4, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, 2211 Wesbrook Mall, Vancouver, BC V6Z 1Y6, Canada.
BC Centre for Disease Control · CAUniversity of British Columbia · CAUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPopulation-level monitoring of hepatitis C virus (HCV) infected people across the cascade of care identifies gaps in access and engagement in care and treatment. We characterized a population-level cascade of care for HCV in British Columbia (BC), Canada and identified factors associated with leakage at each stage.

methodsThe BC Hepatitis Testers Cohort (BC-HTC) includes 1.5million individuals tested for HCV, HIV, reported cases of hepatitis B, and active tuberculosis in BC from 1990 to 2013 linked to medical visits, hospitalizations, cancers, prescription drugs and mortality data. We defined six HCV cascade of care stages: 1) estimated population prevalence; 2) HCV diagnosed; 3) HCV RNA tested; 4) genotyped; 5) initiated treatment; and 6) achieved sustained virologic response (SVR).

resultsWe estimated that 73,203 people were HCV antibody positive in BC in 2012 (undiagnosed: 18,301, 25%; diagnosed: 54,902, 75%). Of these, 56%(40,656) had HCV RNA testing; 34%(26,300) were genotyped; 12%( 8532 ) had received interferon-based therapy and 7%(5197) had SVR. Males, older birth cohorts, and HBV coinfected were less likely to undergo HCV RNA testing. Among those with chronic HCV infection, 32% had received liver-related care. Retention in liver care was more likely in those with HIV, cirrhosis, and drug/alcohol use and less likely in males and HBV coinfected.

conclusionsAlthough there are gaps in HCV RNA testing and genotyping after HCV diagnosis, the major gap in the cascade of care was low treatment initiation. People with comorbidities progressed through the cascade of testing and care but few received treatment.

Indexed as

Delivery of Health CareHepacivirusPopulation SurveillanceAdultAgedAntiviral AgentsBritish ColumbiaCohort StudiesCoinfectionFemaleGenotypeHepatitis CHumansMaleMiddle AgedMolecular TypingAntiviral AgentsRNA, ViralCascade of careEngagement with careHepatitis CLinkage with carePrevalenceTestingTreatment

Identifiers

PMID27596150
PMCPMC5078584
OpenAlexW2516274423

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.